PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ARQT vs. ADMA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARQT and ADMA is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

ARQT vs. ADMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and ADMA Biologics, Inc. (ADMA). The values are adjusted to include any dividend payments, if applicable.

0.00%20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025February
45.57%
42.50%
ARQT
ADMA

Key characteristics

Sharpe Ratio

ARQT:

1.25

ADMA:

3.33

Sortino Ratio

ARQT:

2.10

ADMA:

4.10

Omega Ratio

ARQT:

1.24

ADMA:

1.56

Calmar Ratio

ARQT:

1.15

ADMA:

3.72

Martin Ratio

ARQT:

4.52

ADMA:

18.86

Ulcer Index

ARQT:

21.51%

ADMA:

11.61%

Daily Std Dev

ARQT:

77.19%

ADMA:

65.82%

Max Drawdown

ARQT:

-95.02%

ADMA:

-91.28%

Current Drawdown

ARQT:

-64.58%

ADMA:

-25.29%

Fundamentals

Market Cap

ARQT:

$1.53B

ADMA:

$3.99B

EPS

ARQT:

-$1.67

ADMA:

$0.27

Total Revenue (TTM)

ARQT:

$125.18M

ADMA:

$308.91M

Gross Profit (TTM)

ARQT:

$112.96M

ADMA:

$155.89M

EBITDA (TTM)

ARQT:

-$109.21M

ADMA:

$107.80M

Returns By Period

In the year-to-date period, ARQT achieves a -5.96% return, which is significantly lower than ADMA's -1.46% return.


ARQT

YTD

-5.96%

1M

-10.40%

6M

45.56%

1Y

117.61%

5Y*

-11.99%

10Y*

N/A

ADMA

YTD

-1.46%

1M

-8.35%

6M

42.50%

1Y

226.25%

5Y*

33.56%

10Y*

4.83%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ARQT vs. ADMA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARQT
The Risk-Adjusted Performance Rank of ARQT is 8181
Overall Rank
The Sharpe Ratio Rank of ARQT is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of ARQT is 8282
Sortino Ratio Rank
The Omega Ratio Rank of ARQT is 7777
Omega Ratio Rank
The Calmar Ratio Rank of ARQT is 8282
Calmar Ratio Rank
The Martin Ratio Rank of ARQT is 7979
Martin Ratio Rank

ADMA
The Risk-Adjusted Performance Rank of ADMA is 9797
Overall Rank
The Sharpe Ratio Rank of ADMA is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of ADMA is 9797
Sortino Ratio Rank
The Omega Ratio Rank of ADMA is 9696
Omega Ratio Rank
The Calmar Ratio Rank of ADMA is 9696
Calmar Ratio Rank
The Martin Ratio Rank of ADMA is 9797
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARQT vs. ADMA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ARQT, currently valued at 1.25, compared to the broader market-2.000.002.004.001.253.33
The chart of Sortino ratio for ARQT, currently valued at 2.10, compared to the broader market-4.00-2.000.002.004.002.104.10
The chart of Omega ratio for ARQT, currently valued at 1.24, compared to the broader market0.501.001.502.001.241.56
The chart of Calmar ratio for ARQT, currently valued at 1.15, compared to the broader market0.002.004.006.001.157.50
The chart of Martin ratio for ARQT, currently valued at 4.52, compared to the broader market-10.000.0010.0020.004.5218.86
ARQT
ADMA

The current ARQT Sharpe Ratio is 1.25, which is lower than the ADMA Sharpe Ratio of 3.33. The chart below compares the historical Sharpe Ratios of ARQT and ADMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00SeptemberOctoberNovemberDecember2025February
1.25
3.33
ARQT
ADMA

Dividends

ARQT vs. ADMA - Dividend Comparison

Neither ARQT nor ADMA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ARQT vs. ADMA - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum ADMA drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for ARQT and ADMA. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-64.58%
-25.29%
ARQT
ADMA

Volatility

ARQT vs. ADMA - Volatility Comparison

Arcutis Biotherapeutics, Inc. (ARQT) has a higher volatility of 18.93% compared to ADMA Biologics, Inc. (ADMA) at 15.58%. This indicates that ARQT's price experiences larger fluctuations and is considered to be riskier than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
18.93%
15.58%
ARQT
ADMA

Financials

ARQT vs. ADMA - Financials Comparison

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and ADMA Biologics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab